Karl Sorochinski

Home

The Innovation Antibodies Strike Again

Summary

This April 2016 post explored how large enterprises often suppress internal innovation through excessive governance, risk aversion, and entrenched processes. It told the story of a promising mobile app that was killed not by failure, but by an immune-system response of architecture reviews, compliance fears, and misaligned incentives — a pattern all too familiar in risk-averse organizations.

18-Month Update

By late 2017, forward-thinking companies began introducing innovation sandboxes and fast-track governance lanes to protect early-stage ideas. Embedding risk and compliance partners within teams became a recognized best practice to avoid blind-side rejections.

2025 Insight

Today, innovation in enterprise settings is treated as a collaborative process. Guardrails remain, but are adaptive, and support for change is built into the system. High-performing organizations structure themselves to learn quickly, not just operate safely.

Full Article

Loading content...